Paul Jenkinson - Kite Pharma CFO
CFO
Mr. Paul L. Jenkinson is Chief Financial Officer of the Company. Mr. Jenkinson was employed in several senior executive positions by Allergan, Inc., a Fortune 500 multispecialty company focused on discovering and commercializing innovative pharmaceuticals, biologics, medical devices and overthe counter products in the areas of Ophthalmology, Neurosciences and Medical Aesthetics. From 2008 to 2015 Mr. Jenkinson was Vice President, Global Commercial Finance and Corporationrationrate Finance. From 2006 to 2008 he was Vice President, Corporationrationrate Finance. Prior to joining Allergan, Inc. Mr. Jenkinson was employed by the Black Decker Corporationrationration, a manufacturer of power tools, hardware, home improvement products and technology fastening systems from 1987 to 2008, in positions of increasing responsibility, in England, Germany and the United States. His final position at Black Decker was group finance director and Vice President Corporationrationrate Officer for its Lock Companies within its hardware and home improvement businesses. Prior to joining Black Decker, Mr. Jenkinson worked in New Zealand from 1984 to 1987 for a predecessor company of Fonterra, a cooperative owned by its farmer suppliers and the world largest exporter of dairy products. Mr. Jenkinson commenced his career with Deloitte in New Zealand in 1981. He is a current member of Chartered Accountants Australia and New Zealand since 2016.
| Age | 56 |
| Tenure | 8 years |
| Phone | 310 824-9999 |
| Web | www.kitepharma.com |
Kite Pharma Management Efficiency
Kite Pharma's management efficiency ratios could be used to measure how well Kite Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | CFO Age | ||
| Bren Higgins | KLA Tencor | 54 | |
| Robert McMullan | MACOM Technology Solutions | 63 | |
| Steven Buhaly | Qorvo Inc | 57 | |
| Joanne Solomon | Amkor Technology | 48 | |
| Grant Brown | Qorvo Inc | 47 | |
| Bernard Gutmann | ON Semiconductor | 58 | |
| Mark Murphy | Qorvo Inc | 50 | |
| Thad Trent | ON Semiconductor | 56 | |
| Dror Heldenberg | Valens | 56 | |
| Peter Juhas | AerCap Holdings NV | 52 | |
Management Performance
| Return On Equity | -0.0063 | |||
| Return On Asset | -1.0E-4 |
Kite Pharma Leadership Team
Elected by the shareholders, the Kite Pharma's board of directors comprises two types of representatives: Kite Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kite. The board's role is to monitor Kite Pharma's management team and ensure that shareholders' interests are well served. Kite Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kite Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ran Nussbaum, Independent Director | ||
| Jonathan Peacock, Independent Director | ||
| Shawn Tomasello, Chief Commercial Officer | ||
| Jian Irish, Senior Vice President - Supply Chain | ||
| Cynthia Butitta, CFO and COO | ||
| Franz Humer, Director | ||
| Timothy Moore, Executive Vice President - Technical Operations | ||
| Jeffrey Wiezorek, Vice President - Clinical Development | ||
| Ian Clark, Independent Director | ||
| Steven Ruchefsky, Independent Director | ||
| Joshua Kazam, Director | ||
| Helen Kim, Executive Vice President - Business Development | ||
| Helen MBA, Executive VP of Bus. Devel. | ||
| David Bonderman, Lead Independent Director | ||
| David Chang, Executive Vice President - Research and Development, Chief Medical Officer | ||
| Arie Belldegrun, Executive Chairman of the Board and Presidentident, CEO, Founder | ||
| Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations | ||
| Owen Witte, Director | ||
| Paul Jenkinson, CFO | ||
| Marc Better, VP of Translation Medicine | ||
| Farah Champsi, Independent Director | ||
| Roy Doumani, Independent Director | ||
| Rizwana Sproule, Vice President - Regulatory Affairs | ||
| Margo Roberts, Chief Scientific Officer |
Kite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kite Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0063 | |||
| Return On Asset | -1.0E-4 | |||
| Current Valuation | 9.5 B | |||
| Shares Outstanding | 57.36 M | |||
| Shares Owned By Insiders | 6.93 % | |||
| Shares Owned By Institutions | 90.47 % | |||
| Number Of Shares Shorted | 8.08 M | |||
| Price To Earning | (25.85) X | |||
| Price To Book | 14.47 X | |||
| Price To Sales | 320.94 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Kite Stock
If you are still planning to invest in Kite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kite Pharma's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |